AstraZeneca's $1.275 billion first-in-class therapy fails first phase 3 study AstraZeneca's $1.275 billion first-in-class therapy fails first phase 3...
Day: August 3, 2022
Heterogeneity of the tumor immune microenvironment Heterogeneity of the tumor immune microenvironment.During tumorigenesis and subsequent metastasis, malignant cells gradually...